secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001193125-26-029524
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted
--------------------------------------------------------------------------------

- Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.
- Key secondary endpoint CGI-S also missed (p=0.522).
- eDSP well tolerated; most common adverse events pruritis and pyrexia.
- Company to cease clinical development of eDSP and explore available options.
- Phase 3 NEAT trial enrolled 105 patients with Ataxia-Telangiectasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526029524/0001193125-26-029524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526029524/d61547d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-029524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer